Table 3.
Patient screening and prognosis
| Author | Screening of patients | Targeted drugs at the final follow-up | Deaths |
|---|---|---|---|
| Takaya et al. [9] |
CCC:PVR < 5.0–7.0 Wu\Qp:Qs > 1.5 Left-to-right shunt |
100% | 1 |
| Thomaz et al. [10] | VT: PVR < 6.0 Wu and PVR/SVR < 0.3 | 82% | 3 |
| Huang et al. [11] |
SpO2 > 93% Left-to-right shunt |
– | 0 |
| Hu et al. [12] |
VT: Qp/Qs > 1.5 and PVR/SVR < 2/3 Left-to-right shunt |
63% | 2 |
| Kijima et al. [13] | CCC:Qp/Qs ≥1.5 and PVR < 8 Wu | 100% | 0 |
| Bradley et al. [14] | CCC:PVR < 6.4 Wu and 6MWD > 300 m | – | 0 |
| Liu et al. [15] | SpO2 > 93% | 42% | 0 |
| He et al. [16] | VT:PVR < 5 Wu or Qp/Qs > 1.5 | 86% | 0 |
| Liu et al. [8] | increase of SpO2 > 5% | – | 6 |
CCC conventional cardiac catheterization, VT vasodilation test, Qp:Qs pulmonary to systemic blood flow ratio, SVR systemic vascular resistance